Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) – Equities research analysts at SunTrust Banks increased their FY2019 earnings estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a note issued to investors on Tuesday. SunTrust Banks analyst J. Boris now anticipates that the company will post earnings per share of $0.15 for the year, up from their previous forecast of $0.11. SunTrust Banks also issued estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s FY2021 earnings at $2.16 EPS.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.13. The company had revenue of $39.68 million during the quarter, compared to analyst estimates of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The firm’s revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.08) EPS.

Several other brokerages have also commented on AVDL. Zacks Investment Research lowered shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a report on Monday, October 16th. BidaskClub raised shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Roth Capital set a $14.00 price target on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the stock a “buy” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $21.50.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) traded up $0.73 during midday trading on Friday, reaching $10.51. 631,800 shares of the company traded hands, compared to its average volume of 247,122. The stock has a market cap of $372.38, a price-to-earnings ratio of 5.45 and a beta of 1.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.47 and a current ratio of 1.53. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 12 month low of $7.52 and a 12 month high of $12.30.

A number of institutional investors and hedge funds have recently made changes to their positions in AVDL. PNC Financial Services Group Inc. boosted its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock worth $121,000 after purchasing an additional 10,532 shares during the last quarter. Nine Chapters Capital Management LLC acquired a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth $132,000. Arrowstreet Capital Limited Partnership acquired a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 2nd quarter worth $181,000. Cubist Systematic Strategies LLC acquired a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth $184,000. Finally, State of Tennessee Treasury Department acquired a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 2nd quarter worth $194,000. 67.75% of the stock is currently owned by institutional investors.

In related news, Director Craig R. Stapleton purchased 140,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average price of $8.67 per share, with a total value of $1,213,800.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Craig R. Stapleton sold 254,265 shares of the business’s stock in a transaction on Monday, November 27th. The stock was sold at an average price of $9.35, for a total transaction of $2,377,377.75. Following the completion of the sale, the director now directly owns 253,413 shares of the company’s stock, valued at approximately $2,369,411.55. The disclosure for this sale can be found here. 5.07% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/12/fy2019-eps-estimates-for-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-boosted-by-suntrust-banks-avdl.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Earnings History and Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.